{"id":"NCT01404234","sponsor":"Gilead Sciences","briefTitle":"Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways","officialTitle":"Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa (PA) in the Lower Airways","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-04","completion":"2013-04","firstPosted":"2011-07-28","resultsPosted":"2014-05-01","lastUpdate":"2014-05-29"},"enrollment":61,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis","Pseudomonas Aeruginosa"],"interventions":[{"type":"DRUG","name":"AZLI","otherNames":["Cayston®"]}],"arms":[{"label":"Open-label AZLI","type":"EXPERIMENTAL"}],"summary":"This was an open-label, multicenter study in children ≤ 12 years of age with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa (PA) infection in the lower airways using three 28-day courses of Aztreonam for Inhalation Solution (AZLI) 75 mg three times daily, each followed by 28 days off AZLI. The total treatment duration was to be 6 months.","primaryOutcome":{"measure":"Percentage of Participants Who Discontinued Study Drug Due to Safety or Tolerability Reasons","timeFrame":"Baseline to Day 168","effectByArm":[{"arm":"AZLI","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":13},"locations":{"siteCount":29,"countries":["United States","France","Germany","Italy","Poland","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":61},"commonTop":["Cough","Pyrexia","Nasal congestion","Rhinitis","Rhinorrhoea"]}}